EGF and colorectal carcinoma: Although many questions remain to be answered to uncover the impact of KRASA146T mutation in CRC drug resistance, to our knowledge this is the first description of the effect of this recently discovered mutation on downstream signaling pathways, proliferation, migration and cell adhesion in EGF-stimulated CRC cells.